

## **COVID-19 Vaccine Frequently Asked Questions for Providers**

Updated: May 4, 2021

With the U.S Food & Drug Administration (FDA) authorizing multiple COVID-19 vaccines, Medical Mutual has received many questions from providers regarding the vaccine, our policies and coverage. To assist you, we have prepared the following FAQ.

Updates to this FAQ will be made as more guidance from local and federal governments and other agencies is made available. <u>New information will be highlighted in yellow.</u>

#### Q1. Who is eligible to become a COVID-19 vaccine provider?

A. According to the Ohio Department of Health (ODH), to be eligible to enroll in the COVID-19 Vaccine Program, you must be credentialed/licensed in the state of Ohio through the Ohio Board of Pharmacy, and must have a valid Terminal Distributor of Dangerous Drugs (TDDD) license.

You must also sign and agree to the conditions in the Centers for Disease Control and Prevention (CDC) and Ohio COVID-19 Vaccination Program Provider Agreements available at <u>ohid.ohio.gov</u>.

For additional information on becoming a COVID-19 vaccine provider, review the ODH <u>COVID-19</u> <u>Provider Enrollment</u> page.

#### Q2. How do I become an Ohio COVID-19 vaccine provider?

- A. To enroll as a vaccine provider:
  - 1. Complete, sign and submit the following forms available at <u>ohid.ohio.gov</u>:
    - a. (Section A) CDC COVID-19 Vaccination Provider Agreement
    - b. (Section B) CDC COVID-19 Vaccination Provider Profile
    - c. ODH Outbreak Response Immunization Initiative Agreement
    - d. Impact Statewide Immunization Information System (ImpactSIIS) Security Agreement (if a facility is not already enrolled)
  - 2. Meet program standards for vaccine storage and handling, which include:
    - a. Providers must store and handle the COVID-19 vaccine under proper conditions, including maintaining cold chain conditions and chain of custody at all times in accordance with the manufacturer's package insert and CDC guidance available in the CDC's <u>Vaccine Storage and Handling Toolkit</u>; this toolkit will be updated to include specific information related to COVID-19 vaccine
    - b. Providers must monitor vaccine storage unit temperatures at all times using equipment and practices that comply with guidance located in the CDC's <u>Vaccine</u> <u>Storage and Handling Toolkit</u>
    - c. Providers must comply with immunization program guidance when a vaccine is exposed to temperatures outside of the acceptable range (a temperature excursion)
    - d. Providers must monitor and comply with COVID-19 vaccine expiration dates
    - e. Providers must preserve all records related to COVID-19 vaccine management for a minimum of 3 years or longer if required by state, local, or territorial law
  - 3. Review and be familiar with the <u>CDC's training components</u> of COVID-19 vaccine administration

### Q3. How do I submit the COVID-19 vaccine program agreements?

- A. You can submit the provider agreements at <u>ohid.ohio.gov</u>
  - 1. Log in using your OHID credentials, or create a new account
  - 2. Request access to the Vaccination Program (COVID-19) application
  - 3. Complete, sign and submit all required forms electronically through the application

### Q4. How do I receive the free supplies for administering COVID-19 vaccines?

A. To receive free supplies needed to administer the COVID-19 vaccines, pharmacies, retail clinics, providers and any other site-of-care must sign the <u>CDC and Ohio COVID-19 Vaccination Program</u> <u>Provider Agreements</u>.

#### Q5. What are the reporting requirements for administering COVID-19 vaccines?

A. According to the CDC:

Within 24 hours of administering a dose of the COVID-19 vaccine and adjuvant (if applicable), it must be recorded in the vaccine recipient's record, and the administrator must use their best efforts to report administration data to the relevant system for the jurisdiction, i.e., immunization information system (IIS) as soon as possible and no later than 72 hours after administration. Details of the required information (Vaccine Administration Data) for reporting can be found at <u>cdc.gov/vaccines/covid-19/reporting/index.html</u>.

- Providers must submit Vaccine Administration Data through either (1) the IIS of the state and local or territorial jurisdiction or (2) another system designated by the CDC according to its documentation and data requirements.
- Providers must preserve the record for at least 3 years following vaccination, or longer if required by state, local, or territorial law. Such records must be made available to any federal, state, local or territorial public health department to the extent authorized by law.
- All COVID-19 vaccine providers must report on-hand COVID-19 vaccine inventory each day through the CDC's <u>VaccineFinder</u> website.

#### Q6. Who is covering the cost of the COVID-19 vaccine?

A. COVID-19 vaccines are paid for through funding authorized by the Coronavirus Aid, Relief, and Economic Security (CARES) Act. Providers must administer COVID-19 vaccines regardless of the vaccine recipient's ability to pay COVID-19 vaccine administration fees or whether the recipient has health insurance coverage. Providers may NOT seek any reimbursement, including through balance billing, from the vaccine recipient.

The U.S. Department of Health and Human Services (HHS), through the Health Resources and Services Administration (HRSA), announced a new program covering costs of administering COVID-19 vaccines to patients enrolled in health plans that either do not cover vaccination fees or cover them with patient cost-sharing. The types of plans referenced under this Fund include grandfathered group health plans, excepted benefits, and short-term limited duration insurance. The COVID-19 Coverage Assistance Fund (CAF) will be compensating providers for eligible claims at national Medicare rates which increased in March. For more information, please see this <u>fact</u> <u>sheet</u> and <u>FAQs</u>.

COVID-19 Vaccine Administration Coverage	
Commercial and Individual Plan Members	Medical Mutual will cover COVID-19 vaccine administration, regardless of the number of doses, under both medical and pharmacy benefits at no cost sharing for members.
Commercial – Grandfathered and Non-grandfathered Plan Members	Medical Mutual will cover the cost of the administration of the vaccines at no cost sharing for members.

Medicare Advantage and Medicare	Both the vaccines and its administration are paid for by
Supplement Plan Members	Original Medicare at least through 2021.

# Q7. Will all of the COVID-19 vaccines that are or will be authorized by the FDA follow the same coverage rules?

A. Yes. All of the COVID-19 vaccines that are or will be authorized by the FDA will follow the same coverage rules.

# Q8. How do I submit claims for administering the COVID-19 vaccine to Medicare Advantage and Medicare Supplement plan members?

A. If you administer the vaccine to a Medicare Advantage or Medicare Supplement plan member, you should submit claims to Original Medicare through your Medicare Administrative Contractor (MAC) for 2020 and 2021. If you do not know who your MAC is, you can find out on the <u>CMS website</u>.

When COVID-19 vaccine doses are provided by the government without charge, only bill for the vaccine administration. Don't include the vaccine codes on the claim when the vaccines are free.

For more information on submitting COVID-19 administrative claims to your MAC, please reference the CMS Provider Toolkit at <u>cms.gov/medicare/covid-19/medicare-billing-covid-19-vaccine-shot-administration</u>.

#### Q9. Who is eligible to receive the COVID-19 vaccines?

A. All individuals 16 and older are eligible to receive the vaccine. This will continue to change as vaccines are approved for children under 16.

#### Q10. What clinical codes should be used for the COVID-19 vaccines and administration?

- A. The clinical codes for the COVID-19 vaccines and administration are:
  - Pfizer 91300 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (COVID-19) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3mL\_dosage, diluent reconstituted, for intramuscular use
    - 0001A <u>Immunization administration</u> by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (COVID-19) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/ 0.3mL dosage, diluent reconstituted; first dose
    - 0002A <u>Immunization administration</u> by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (COVID-19) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/ 0.3mL dosage, diluent reconstituted; second dose
  - Moderna 91301 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (COVID-19) vaccine, mRNA-LNP, spike protein, preservative free, 100 mcg/0.5mL dosage, for intramuscular use
    - 0011A <u>Immunization administration</u> by intramuscular injection of Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (COVID-19) vaccine, mRNA-LNP, spike protein, preservative free, 100 mcg/ 0.5mL dosage; first dose
    - 0012A <u>Immunization administration</u> by intramuscular injection of Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (COVID-19) vaccine, mRNA-LNP, spike protein, preservative free, 100 mcg/ 0.5mL dosage; second dose